

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450. Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	10.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,984		03/03/2004	Jotham W. Coe	PC25421A 4866	
23913	7590	09/22/2006		EXAMINER	
PFIZER	. INC T 42ND STE	Deer	ZHANG, NANCY L		
	OOR - STOP			ART UNIT	PAPER NUMBER
NEW YO	ORK, NY I	0017-5612	1614		
			DATE MAN ED 00/00/000		

DATE MAILED: 09/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/791,984	COE ET AL.					
Office Action Summary	Examiner	Art Unit					
	Nancy L. Zhang	1614					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence addres	ss				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	J. ely filed the mailing date of this commu 0 (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 03 M	arch 2004.						
	action is non-final.						
3) Since this application is in condition for allowar		secution as to the me	erits is				
closed in accordance with the practice under E	•						
Disposition of Claims	,,,,						
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	n from consideration						
5) Claim(s) is/are allowed.	m nom consideration.						
· · · · · · · · · · · · · · · · · · ·							
7) Claim(s) is/are objected to.	Claim(s) is/are rejected.						
8) Claim(s) 1-25 are subject to restriction and/or e	election requirement						
Olaim(s) 1-20 are subject to restriction and/or e	rection requirement.						
Application Papers							
9) The specification is objected to by the Examiner	•.						
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the E	xaminer.					
Applicant may not request that any objection to the o	drawing(s) be held in abeyance. See	37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1	.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-1	152.				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f).					
a) All b) Some * c) None of:							
<ol> <li>Certified copies of the priority documents</li> </ol>	have been received.						
2. Certified copies of the priority documents	have been received in Application	on No					
3. Copies of the certified copies of the prior	ity documents have been receive	d in this National Sta	ge				
application from the International Bureau	(PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of	of the certified copies not receive	d.					
Attachment(s)							
Notice of References Cited (PTO-892)	4) Interview Summary						
2)	Paper No(s)/Mail Da 5) Notice of Informal Pa						
Paper No(s)/Mail Date	6) Other:						

## **DETAILED ACTION**

## Election/Restrictions

This application contains claims directed to the following patentably distinct species:

- (A) The pharmaceutical composition comprises (a) a nicotinic receptor partial agonist and (b) a CB-1 receptor antagonist where the two compounds are mixed together as a mixture. The applicant is required to specify one single compound for (a) and one single compound for (b) in the mixture.
- (B) The pharmaceutical composition comprises (a) a nicotinic receptor partial agonist and (b) a CB-1 receptor antagonist where the two compounds are not mixed together. The applicant is required to specify one single compound for (a) and one single compound for (b) in the composition.

The species are independent or distinct because they are different compounds. Different compounds have different structures, binding activities and biological effects. Searching for one compound is not likely to result in finding art pertinent to any other compounds. In addition, because compound (a) and compound (b) are two different compounds, the interactions between every two different compounds are different and the biological effects would be different when the two different compounds are being administered as a mixture or being administered separately and therefore resulting in different pharmaceutically effects.

Application/Control Number: 10/791,984

Art Unit: 1614

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, all claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## **Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy L. Zhang whose telephone number is (571)-272-8270. The examiner can normally be reached on Mon.- Fri. 8:30am - 5:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/791,984 Page 5

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

nemy 9/8/06

NLZ

ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER